Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy

3 Jul 2019

Abstract excerpt

Immune checkpoint inhibitors are among the newest, cutting-edge methods for the treatment of cancer. Currently, they primarily influence T cell adaptive immunotherapy targeting the PD-1/PD-L1 and CTLA-4/B7 signalling pathways. These inhibitors fight cancer by reactivating the patient's own adaptive immune system, with good results in many cancers. With the discovery of the "Don't Eat Me" molecule, CD47,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31267559
DOI: 10.1111/sji.12804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapyPMID 31267559Read ↗

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα AxisSemantic proximity Read ↗

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapySemantic proximity Read ↗

Leveraging NKG2D Ligands in Immuno-OncologySemantic proximity Read ↗

Breaking the ‘Don’t Eat Me’ Signal: In Silico Design of CD47 Directed Peptides for Cancer ImmunotherapySemantic proximity Read ↗

Blockade of CD47 or SIRPα: a new cancer immunotherapySemantic proximity Read ↗

The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategiesSemantic proximity Read ↗

Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cellsSemantic proximity Read ↗

Recent Advances of Tumor Therapy Based on the CD47-SIRPα AxisSemantic proximity Read ↗

Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?Semantic proximity Read ↗

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.Semantic proximity Read ↗

CD47 predominates over CD24 as a macrophage immune checkpoint in cancerSemantic proximity Read ↗

Mechanisms of induction of regulatory B cells in the tumour microenvironment and their contribution to immunosuppression and pro-tumour responsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.